PARP inhibitors show promise for hard-to-treat breast cancers

Bookmark and Share
Published: 25 Jun 2009
Views: 12697
Dr. Andrew Tutt - Breakthrough Breast Cancer Research Unit, Kings College London, UK
A study reports that women with BRCA deficient advanced breast cancer experienced tumour shrinkage after receiving the PARP inhibitor olaparib as a single agent.